Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
Phase 3 Clinical Trial
Advertisement
AusperBio Raises $120M to Advance Next-Gen HBV Therapies
SAN FRANCISCO, Aug 27, 2026 AusperBio Therapeutics has completed a $120 million Series C financing to accelerate the development...
BeOne Wins FDA Approval for TEVIMBRA HER2+ GEA Regimen
SAN CARLOS, Calif., August 25, 2026 BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Werewolf Therapeutics and Ambros Announce $150M Merger
Waltham, Massachusetts, USA, and San Diego, California, USA, August 21, 2026 Werewolf Therapeutics and Ambros Therapeutics have announced a...
Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care
Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...
Advertisements
Ultragenyx Wins FDA Approval for GENGLYCOS Gene Therapy
Novato, California, August 19, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) granted...
Amylyx Pharmaceuticals Reports Positive Phase 3 Results
CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals, Inc. announced positive topline results from the Phase 3 LUCIDITY clinical trial...
Zai Lab and argenx Report Positive ALKIVIA Phase 3 Results
SHANGHAI, China / CAMBRIDGE, Massachusetts / AMSTERDAM, Netherlands — August 17, 2026 Zai Lab Limited and argenx announced positive...
Amylyx to Report Phase 3 Avexitide Results August 18
CAMBRIDGE, Mass., August 17, 2026 Amylyx Pharmaceuticals, Inc. announced that it will report topline results from the Phase 3...
Evaxion Advances AI-Designed EVX-05 Brain Cancer Vaccine
Copenhagen, Denmark — August 17, 2026 Evaxion A/S has expanded and refocused its cancer vaccine pipeline with EVX-05, an...
Advertisement
